CA3028924A1 - Salbutamol-containing ophthalmic medicament - Google Patents

Salbutamol-containing ophthalmic medicament Download PDF

Info

Publication number
CA3028924A1
CA3028924A1 CA3028924A CA3028924A CA3028924A1 CA 3028924 A1 CA3028924 A1 CA 3028924A1 CA 3028924 A CA3028924 A CA 3028924A CA 3028924 A CA3028924 A CA 3028924A CA 3028924 A1 CA3028924 A1 CA 3028924A1
Authority
CA
Canada
Prior art keywords
composition
salbutamol
administered
ranging
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3028924A
Other languages
English (en)
French (fr)
Inventor
Raouf Rekik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3028924A1 publication Critical patent/CA3028924A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3028924A 2016-06-27 2017-06-27 Salbutamol-containing ophthalmic medicament Pending CA3028924A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TNTN2016/0259 2016-06-27
TN2016000259A TN2016000259A1 (en) 2016-06-27 2016-06-27 Salbutamol (albuterol) eye protective medicament.
PCT/IB2017/000779 WO2018007864A1 (en) 2016-06-27 2017-06-27 Salbutamol-containing ophthalmic medicament

Publications (1)

Publication Number Publication Date
CA3028924A1 true CA3028924A1 (en) 2018-01-11

Family

ID=59416735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3028924A Pending CA3028924A1 (en) 2016-06-27 2017-06-27 Salbutamol-containing ophthalmic medicament

Country Status (8)

Country Link
US (1) US11484513B2 (https=)
EP (1) EP3474836B1 (https=)
JP (1) JP7176960B2 (https=)
CN (1) CN110114066B (https=)
CA (1) CA3028924A1 (https=)
MA (1) MA45457A (https=)
TN (1) TN2016000259A1 (https=)
WO (1) WO2018007864A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020178721A1 (en) * 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
EP3979996A4 (en) * 2019-06-10 2023-06-14 Jenivision Inc. METHODS AND FORMULA FOR THE TREATMENT OF VISUAL DISORDERS
JP7066293B2 (ja) * 2019-11-12 2022-05-13 株式会社ファンケル サーチュイン１（ｓｉｒｔ１）発現増強用組成物
JP2023526517A (ja) * 2020-05-22 2023-06-21 イントラビオ エルティーディー 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ
CN120916785A (zh) * 2023-04-08 2025-11-07 林颂然 治疗角膜损伤的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985897A (en) * 1973-12-21 1976-10-12 Mead Johnson & Company Ocular hypotensive process employing dextrorotatory sulfonamidophenethanolamines
SE8701258D0 (sv) * 1987-03-26 1987-03-26 Pharmacia Ab A composition for the topical treatment of glaucoma or ocular hypertension
US5192780A (en) * 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
US6569903B2 (en) * 1999-12-07 2003-05-27 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
WO2003049745A1 (en) 2001-12-12 2003-06-19 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
CA2591406A1 (en) 2004-12-17 2006-06-22 Cipla Limited Pharmaceutical compounds and compositions
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US20110294897A1 (en) * 2009-12-02 2011-12-01 Bridge Pharma, Inc. Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
WO2014191414A1 (en) * 2013-05-28 2014-12-04 Sanovel Ilac Sanayi Ve Ticaret A.S. Syrup formulation of salbutamol

Also Published As

Publication number Publication date
JP7176960B2 (ja) 2022-11-22
RU2018146575A (ru) 2020-07-28
CN110114066B (zh) 2023-06-27
WO2018007864A1 (en) 2018-01-11
EP3474836B1 (en) 2024-01-17
EP3474836C0 (en) 2024-01-17
EP3474836A1 (en) 2019-05-01
JP2019524679A (ja) 2019-09-05
CN110114066A (zh) 2019-08-09
US11484513B2 (en) 2022-11-01
RU2018146575A3 (https=) 2020-09-24
US20190160027A1 (en) 2019-05-30
MA45457A (fr) 2019-05-01
TN2016000259A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
Lee et al. Glaucoma and its treatment: a review
Razeghinejad et al. Iatrogenic glaucoma secondary to medications
Benozzi et al. Presbyopia treatment with eye drops: an eight year retrospective study
US11484513B2 (en) Salbutamol-containing ophthalmic medicament
Tătaru et al. Antiglaucoma pharmacotherapy
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
JP2005501100A (ja) 視力を改善する生理学的方法
Guo et al. Scleral cross-linking in form-deprivation myopic guinea pig eyes leads to glaucomatous changes
Wood et al. Rare corneal complication following selective laser trabeculoplasty
Hashemian et al. Ocular presentations of amyloidosis
Marais et al. The medical management of glaucoma
Galloway et al. The Ageing Eye
Thakur et al. Glaucoma: a review
RU2774971C2 (ru) Офтальмологическое лекарственное средство, содержащее сальбутамол
Kartasasmita et al. The effectiveness of continuous intravitreal adrenaline as mydriatic adjuvant on pars plana vitrectomy in diabetic patient, a randomized clinical trial
Mentes et al. Do mydriatics effect serous pigment epithelial detachment elevation? A case report on central serous chorioretinopathy
Schellack et al. Glaucoma: a brief update for 2017
Stradiotto et al. Glaucoma pharmacology
Small The clinical handbook of ophthalmology
Song et al. Success in The Duke Elder Examination: 180 MCQs
Purbrick et al. Eye disease in older people
Ramlal Interventional Follow Up Study of Resolution of Macular Edema After Intravitreal Triamcinolone Injection in Pseudophakic Patients with Macular Edema More than 350 Micron
CN119258066A (zh) Alw-ii-41-27在治疗眼科疾病中的新应用
Jacob et al. Ocular Findings in Diabetics and Hypertensives Undergoing Hemodialysis
Khodake et al. Our Patient has High Eye Pressure: Is it a Problem?(Raised Intraocular Pressure-Glaucoma)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191015

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250806

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250806

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251015

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251015

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251217

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260226